Clinical Trial Update: An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation [Phase 4]

View source ↗

Summary

This Phase 4 open-label trial assessed the safety and effectiveness of adalimumab for moderate to severe plaque psoriasis in the Russian Federation, with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Humira (adalimumab)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Moderate to Severe Plaque Psoriasis | Phase 4 | Status: COMPLETED | Results posted: 2014-09-17